Immunoglobulin lambda variable 3-21 R110 neoepitope (IGLV3-21^R110^)

The Immunoglobulin lambda variable 3-21 R110 (IGLV3-21^R110^) neoepitope is a tumor-specific structural motif found on the B-cell receptor (BCR) of a high-risk subset of Chronic Lymphocytic Leukemia (CLL) patients (Minici et al., 2017). This neoepitope is defined by the presence of an arginine residue at position 110, which typically arises through somatic hypermutation or specific V-J gene recombination (Stamatopoulos et al., 2018). The R110 residue is functionally significant as it mediates homotypic BCR-BCR interactions, leading to autonomous, antigen-independent signaling that promotes leukemic cell survival and proliferation (Minici et al., 2017). This specific BCR configuration is the hallmark of "subset 2" CLL, which is clinically characterized by an aggressive disease course and poor response to conventional therapies (Nadeu et al., 2021). Because the R110-containing light chain is absent in healthy B cells, it represents an ideal neoantigen for precision immunotherapy. Experimental therapeutic approaches include chimeric antigen receptor (CAR) T-cells and monoclonal antibodies specifically engineered to recognize the R110-mutated epitope while sparing normal B cells. Targeting this neoepitope aims to provide a highly selective treatment option for patients with the most aggressive forms of CLL.

Other names

IGLV3-21*01 R110Subset 2 CLL B-cell receptorR110-mutated immunoglobulin lambda light chainIGLV3-21-containing B-cell receptor

Selective binding to the R110-mutated immunoglobulin lambda light chain to induce immune-mediated cytotoxicity against malignant B cells.